Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.
The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.
The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: Thomas.Powles@bartshealth.nhs.uk.
Thomas
T
Powles
Department of Urology, Ludwig-Maximilians University, Munich, Germany.
Michael
M
Staehler
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Börje
B
Ljungberg
Department of Urology, University of Rennes, Rennes, France.
Karim
K
Bensalah
Division of Urology, University of Texas Medical School at Houston, Houston, TX, USA.
Steven E
SE
Canfield
Department of Urology, Skåne University Hospital, Malmö, Sweden.
Saeed
S
Dabestani
Patient Advocate International Kidney Cancer Coalition (IKCC); University Medical Center Utrecht, Nephrology Department, Utrecht, The Netherlands.
Rachel
R
Giles
Department of Urology, Sunderby Hospital, Sunderby, Sweden.
Fabian
F
Hofmann
Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
Milan
M
Hora
Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
Markus A
MA
Kuczyk
Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
Thomas
T
Lam
Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
Lorenzo
L
Marconi
Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Axel S
AS
Merseburger
Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
Alessandro
A
Volpe
Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Axel
A
Bex
D000813:Anilides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D000068338:Everolimus / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D000077594:Nivolumab; D017410:Practice Guidelines as Topic; D011725:Pyridines / Q000627:therapeutic use*; D019233:Retreatment; D017211:Treatment Failure; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000813:Anilides; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; C558660:cabozantinib; D000077594:Nivolumab; D000068338:Everolimus